Braveheart Bio, Inc. — insider transactions
34 transactions on record · BRVE · CIK 2131524
Aggregates
computed from the filings belowPurchases, 12m
13
count of open-market buys
Sales, 12m
21
count of open-market sales
Buy / sell ratio, 12m
0.62
purchases per sale
Distinct insiders, 12m
13
Bought, 3m
$89.6M
Sold, 3m
$0
Median disclosure lag
2.0 d
trade date to filing date
Largest single trade, 24m
$34.6M
2026-08-07
Director share, 12m
55.9%
of transactions where role is stated
Current run
1 sells
consecutive same-direction transactions
Net 3m flow
$89.6M
purchases minus sales
Total on record
34
Transactions
34 most recent shown| Disclosed | Recorded (UTC) | Traded | Lag, d | Insider | Role | Transaction | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | 2026-08-12 02:21:37.630 UTC | 2026-08-07 | 4 | HOROWITZ BENJAMIN A | 10% Owner | Conversion of derivative | 9,132,420 | — | — | filing |
| 2026-08-11 | 2026-08-12 02:21:37.630 UTC | 2026-08-07 | 4 | HOROWITZ BENJAMIN A | 10% Owner | Open market purchase | 1,100,000 | $18.00 | $19.8M | filing |
| 2026-08-11 | 2026-08-12 02:21:37.630 UTC | 2026-08-07 | 4 | HOROWITZ BENJAMIN A | 10% Owner | Conversion of derivative | 40,000,000 | $0.00 | — | filing |
| 2026-08-11 | 2026-08-12 02:24:00.580 UTC | 2026-08-07 | 4 | OrbiMed Genesis GP LLC | Director, 10% Owner | Open market purchase | 273,333 | $18.00 | $4.9M | filing |
| 2026-08-11 | 2026-08-12 02:24:00.781 UTC | 2026-08-07 | 4 | Chimovits Erez | Director, 10% Owner | Open market purchase | 273,333 | $18.00 | $4.9M | filing |
| 2026-08-11 | 2026-08-12 02:24:00.580 UTC | 2026-08-07 | 4 | OrbiMed Genesis GP LLC | Director, 10% Owner | Open market purchase | 1,666,667 | $18.00 | $30M | filing |
| 2026-08-11 | 2026-08-12 02:24:00.781 UTC | 2026-08-07 | 4 | Chimovits Erez | Director, 10% Owner | Open market purchase | 1,666,667 | $18.00 | $30M | filing |
| 2026-08-11 | 2026-08-12 02:24:00.580 UTC | 2026-08-07 | 4 | OrbiMed Genesis GP LLC | Director, 10% Owner | Conversion of derivative | 9,132,420 | — | — | filing |
| 2026-08-11 | 2026-08-12 02:24:00.580 UTC | 2026-08-07 | 4 | OrbiMed Genesis GP LLC | Director, 10% Owner | Conversion of derivative | 40,000,000 | $0.00 | — | filing |
| 2026-08-11 | 2026-08-12 02:24:00.781 UTC | 2026-08-07 | 4 | Chimovits Erez | Director, 10% Owner | Conversion of derivative | 9,132,420 | — | — | filing |
| 2026-08-11 | 2026-08-12 02:24:00.781 UTC | 2026-08-07 | 4 | Chimovits Erez | Director, 10% Owner | Conversion of derivative | 40,000,000 | $0.00 | — | filing |
| 2026-08-10 | 2026-08-11 02:20:16.159 UTC | 2026-08-07 | 3 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% Owner | Conversion of derivative | 7,420,091 | — | — | filing |
| 2026-08-10 | 2026-08-11 02:20:16.159 UTC | 2026-08-07 | 3 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% Owner | Conversion of derivative | 32,500,000 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:18:41.838 UTC | 2026-08-05 | 2 | Anderson Michele A. | Chief Development Officer | Grant or award | 300,000 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:18:41.838 UTC | 2026-08-07 | 0 | Anderson Michele A. | Chief Development Officer | Open market purchase | 1,111 | $18.00 | $20K | filing |
| 2026-08-07 | 2026-08-08 03:19:00.835 UTC | 2026-08-07 | 0 | Forbion Ventures VII Management B.V. | 10% Owner | Conversion of derivative | 7,990,867 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:19:03.215 UTC | 2026-08-05 | 2 | Viehbacher Christopher | Director | Grant or award | 30,000 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:19:03.763 UTC | 2026-08-05 | 2 | Chimovits Erez | Director, 10% Owner | Grant or award | 30,000 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:19:00.835 UTC | 2026-08-07 | 0 | Forbion Ventures VII Management B.V. | 10% Owner | Conversion of derivative | 40,000,000 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:19:02.580 UTC | 2026-08-07 | 0 | Malek David I | Director | Open market purchase | 4,166 | $18.00 | $75K | filing |
| 2026-08-07 | 2026-08-08 03:19:02.205 UTC | 2026-08-07 | 0 | Murdoch Travis | Director, CEO and President | Open market purchase | 83,333 | $18.00 | $1.5M | filing |
| 2026-08-07 | 2026-08-08 03:19:00.835 UTC | 2026-08-07 | 0 | Forbion Ventures VII Management B.V. | 10% Owner | Conversion of derivative | 9,132,420 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:19:02.580 UTC | 2026-08-05 | 2 | Malek David I | Director | Grant or award | 30,000 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:19:03.215 UTC | 2026-08-07 | 0 | Viehbacher Christopher | Director | Open market purchase | 83,333 | $18.00 | $1.5M | filing |
| 2026-08-07 | 2026-08-08 03:19:00.835 UTC | 2026-08-07 | 0 | Forbion Ventures VII Management B.V. | 10% Owner | Open market purchase | 1,680,000 | $18.00 | $30.2M | filing |
| 2026-08-07 | 2026-08-08 03:19:02.205 UTC | 2026-08-05 | 2 | Murdoch Travis | Director, CEO and President | Grant or award | 550,000 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:18:58.594 UTC | 2026-08-05 | 2 | Bos Jasper | Director | Grant or award | 30,000 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:19:00.835 UTC | 2026-08-07 | 0 | Forbion Ventures VII Management B.V. | 10% Owner | Conversion of derivative | 35,000,000 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:19:01.582 UTC | 2026-08-07 | 0 | Lubner David Charles | Director | Open market purchase | 55,555 | $18.00 | $1M | filing |
| 2026-08-07 | 2026-08-08 03:19:01.582 UTC | 2026-08-05 | 2 | Lubner David Charles | Director | Grant or award | 60,000 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:19:00.835 UTC | 2026-08-07 | 0 | Forbion Ventures VII Management B.V. | 10% Owner | Open market purchase | 1,920,000 | $18.00 | $34.6M | filing |
| 2026-08-07 | 2026-08-08 03:19:04.541 UTC | 2026-08-05 | 2 | Rickey James Paul | Chief Financial Officer | Grant or award | 300,000 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:19:04.169 UTC | 2026-08-05 | 2 | Lohoff Tim | Director | Grant or award | 30,000 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-08 03:19:04.541 UTC | 2026-08-07 | 0 | Rickey James Paul | Chief Financial Officer | Open market purchase | 27,777 | $18.00 | $500K | filing |